(Q35917349)

11 August 2017

1 reference

title

The impact of the M184V substitution on drug resistance and viral fitness (English)

1 reference

11 August 2017

1

Mark A Wainberg

1 reference

11 August 2017

publication date

1 February 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

147-151

1 reference

Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

Impact of drug resistance mutations on virologic response to salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.147

21 January 2018

Identifiers

DOI

10.1586/14787210.2.1.147

1 reference

11 August 2017

1 reference